Ignite Creation Date:
2024-05-06 @ 8:18 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06335134
Status:
RECRUITING
Last Update Posted:
2024-03-28
First Post:
2023-07-29
Brief Title:
A Drug-Drug Interaction Study Between XW003 and Metformin Warfarin Rosuvastatin or Digoxin
Sponsor:
Hangzhou Sciwind Biosciences Co Ltd
Organization:
Hangzhou Sciwind Biosciences Co Ltd
Study Overview
Official Title:
A Single-Center Open-Label Study to Evaluate the Effect of XW003 Injection on the Pharmacokinetics of Metformin Warfarin Rosuvastatin or Digoxin in Healthy Subjects
Status:
RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study of a drug-drug interaction between XW003 and Metformin Warfarin Rosuvastatin or Digoxin
Detailed Description:
This is a single-center open-label fixed-sequence study designed to assess the effect of once-weekly subcutaneous injections of XW003 on the pharmacokinetics of metformin warfarin rosuvastatin or digoxin Approximately 56 healthy subjects are to be enrolled into 2 parallel trial groups with 28 subjects and 2 drugs evaluated in each of the trial group
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None